RxDoctor Payments Data

Rebecca Raj, MD

Internal Medicine · Newburgh, INNPI 1194256180

Payments from drug & device makers

$975in general payments, 2019–2025

Across 58 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$165
  • Novo Nordisk$160
  • Pfizer$107
  • Merck$102
  • GSK$99
  • Lilly USA, LLC$86
  • plus $255 from 13 others

What the payments were for

  • Food & beverage$93095%
  • Education$455%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$975 in reported general payments places this provider in the 75th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$128,986
Medicare patients
406
Services billed
1,279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$105,187
JardianceEmpagliflozin91$98,348
EliquisApixaban83$76,709
MounjaroTirzepatide64$76,279
XareltoRivaroxaban41$49,414
TrulicityDulaglutide26$41,359
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$25,838
MyrbetriqMirabegron31$21,239
TradjentaLinagliptin19$19,869
FarxigaDapagliflozin Propanediol12$16,160
JanuviaSitagliptin Phosphate20$13,032
Metaxalone11$8,884
TrulancePlecanatide12$7,211
Incruse ElliptaUmeclidinium Bromide18$6,440
Advair HfaFluticasone Propion/Salmeterol14$6,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$15$118,217110 claims
Lilly USA, LLCMounjaro, Trulicity$86$117,63990 claims
Novo NordiskOzempic$160$105,18767 claims
PfizerEliquis$107$76,70983 claims
Johnson & JohnsonXarelto$27$49,41441 claims
GSKTrelegy Ellipta, Incruse Ellipta$99$32,27852 claims
MerckJanuvia$102$13,03220 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$14$7,21112 claims
AbbVieSynthroid$165$5,52157 claims
Sanofi-aventis U.S. LLCLantus$12$2,40212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Newburgh

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →